Newsfeeds Archive - Page 78 of 167

2 minute read

General

Infobird Says Recently Engaged With A ‘multinational enterprise’ Deploy Its Retail Rubik’s Cube

September 12, 9:06 AM

Infobird Co., Ltd (NASDAQ:IFBD) ("Infobird" or the "Company"), a leading provider of AI-powered customer engagement solutions in China, today announced that it has recently engaged with a

IFBD

3 minute read

Onconova Therapeutics Announces Updated Data From Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib In Combination With Nivolumab In Advanced KRAS-Mutated Non-Small Cell Lung Cancer At The ESMO Congress 2022

By Bill Haddad

September 12, 8:04 AM

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3

ONTX

1 minute read

Phio Pharmaceuticals Announces Acceptance Of Six Abstracts At The 37th Annual Meeting Of The Society For Immunotherapy Of Cancer

By Bill Haddad

September 12, 7:34 AM

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

PHIO

3 minute read

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During ‘Spotlight on the Clinic’ Virtual Event

By Bill Haddad

September 12, 7:06 AM

- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined Focus on

DYN

1 minute read

Legal
News

Two US House Committee Chairs Wants Inspector General To Probe If Airlines Used Government Funds For Pilot Buyouts, Early Retirements

By Bill Haddad

September 9, 8:34 AM

-Reuters

AAL

1 minute read

Arcutis Biotherapeutics Presents Data From STRATUM Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Seborrheic Dermatitis Presented At European Academy Of Dermatology And Venereology Congress

By Bill Haddad

September 9, 8:16 AM

Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle

ARQT

1 minute read

OFS Credit Q3 EPS $0.42 Down From $0.58 YoY

By Bill Haddad

September 9, 8:05 AM

OFS Credit (NASDAQ:OCCI) reported quarterly earnings of $0.42 per share. This is a 27.59 percent decrease over earnings of $0.58 per share from the same period last year.

OCCI

1 minute read

News

NovaBay Pharmaceuticals Enters Into Agreements For A Private Placement And Warrant Reprice Transactions To Raise Up To $5.3M

By Bill Haddad

September 9, 8:04 AM

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a

NBY

1 minute read

AstraZeneca And Merck Announce Long-Term Follow Up Results From Phase 3 PAOLA-1 And SOLO-1 Trials

By Bill Haddad

September 9, 8:02 AM

Five-year follow-up of the Phase 3 PAOLA-1 trial showed LYNPARZA plus bevacizumab provided a clinically meaningful improvement in overall survival in a subgroup of HRD-positive patients, with 65.5% of patients

AZN

1 minute read

ABM Industries Q3 EPS $0.94 Beats $0.90 Estimate, Sales $2.00B Beat $1.91B Estimate

By Bill Haddad

September 9, 6:59 AM

ABM Industries (NYSE:ABM) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.90 by 4.44 percent. This is a 4.44 percent increase over earnings of $0.90 per share from the same

ABM